Medios AG (XTRA:ILM1) signed a purchase agreement to acquire CRANACH PHARMA GmbH from BMSH GmbH for approximately €120 million on November 26, 2020. As a part of consideration, 4.18 million new shares of Medios AG will be issued from authorized capital, which amounts to €120.8 million based on a share price of approximately €28.90 per Medios share. These new shares are subject to staggered lock-up periods of up to 24 months. In addition, Medios will provide funds of approximately €30 million in the course of the acquisition of Cranach in order to strengthen working capital and finance further growth. For the year ending December 31, 2019, Cranach reported sales of around €503 million, an EBITDA of around €16.3 million and an EBT of around €15.3 million. The transaction is subject to approval by the German Federal Cartel Office. As of December 21, 2020, The German Federal Cartel Office has approved the transaction. The closing of the transaction is expected for the first quarter of 2021. Medios AG (XTRA:ILM1) completed the acquisition of CRANACH PHARMA GmbH from BMSH GmbH on January 21, 2021. With the entry of the capital increase in kind in the commercial register, all closing conditions have now been fulfilled, meaning that the acquisition is completed. For the 2021 financial year, Medios expects, including the acquired Cranach Pharma GmbH, a significant increase in group sales to more than €1 billion. As part of the acquisition, Medios will provide Cranach Pharma with funding of approximately €30 million to strengthen its working capital and finance further growth.